1033: McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, 
DeVries T, Sheikh NA, Dreicer R. A transient increase in eosinophils is
associated with prolonged survival in men with metastatic castration-resistant
prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014
Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4. PubMed
PMID: 25189164; PubMed Central PMCID: PMC4185225.


1034: McNeel DG, Becker JT, Johnson LE, Olson BM. DNA Vaccines for Prostate
Cancer. Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263. PubMed PMID: 24587772;
PubMed Central PMCID: PMC3935480.


1035: McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL,
Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and
immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in
patients with stage D0 prostate cancer. J Clin Oncol. 2009 Sep 1;27(25):4047-54. 
doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27. PubMed PMID: 19636017; PubMed
Central PMCID: PMC2734418.


1036: McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol. 2007
May;17(3):175-81. Review. PubMed PMID: 17414515.


1037: McNeel DG. Cellular immunotherapies for prostate cancer. Biomed
Pharmacother. 2007 Jul;61(6):315-22. Epub 2007 Jan 26. Review. PubMed PMID:
17306498.


1038: McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol
Lett. 2005 Jan 15;96(1):3-9. Review. PubMed PMID: 15585302.